Koczywas M, Williams AC, Cristea M, Reckamp K, Grannis F, Tiep BL, Uman G, Ferrell B. Longitudinal Changes in Function, Symptom Burden and Quality of Life in Patients with Early Stage Lung Cancer. Ann Surg Oncol 2012 Nov 10. 

Benz MR, Herrmann K, Walter F, Geron EB, Reckamp KL, Figlin R, Phelps ME, Weber WA, Czernin J, Allen-Auerbach MS. 18F-FDG PET/CT for monitoring treatment responses to the epidermal growth factor receptor inhibitor erlotinib. J Nucl Med 2011; 53: 1684-9. 

Xin H, Herrmann A, Reckamp K, Zhang W, Pal S, Hedvat M, Zhang C, Liang W, Scuto A, Morosini D, Cao ZA, Zinda M, Figlin R, Huszar D, Jove R, Yu H. Anti-angiogenic and anti-metastatic activity of JAK inhibitor AZD1480. Cancer Res 2011. 

Ramalingam SS, Davies AM, Longmate J, Edelman MJ, Lara PN Jr, Vokes EE, Villalona-Calero M, Gitlitz B, Reckamp K, Salgia R, Wright JJ, Belani CP, Gandara DR. Bortezomib for Patients with Advanced-Stage Bronchioloalveolar Carcinoma: A California Cancer Consortium Phase II Study (NCI 7003). J Thorac Oncol 2011.

Lara PN Jr, Longmate J, Reckamp K, Gitlitz B, Argiris A, Ramalingam S, Belani CP, Mack PC, Lau DH, Koczywas M, Wright JJ, Shepherd FA, Leighl N, Gandara DR. Randomized Phase II Trial of Concurrent Versus Sequential Bortezomib Plus Docetaxel in Advanced Non-Small-Cell Lung Cancer: A California Cancer Consortium Trial. Clin Lung Cancer. 2011;12:33-7. 

Kujawski M, Zhang C, Herrmann A, Reckamp K, Scuto A, Jensen M, Deng J, Forman S, Figlin R, Yu H. Targeting Stat3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects. Cancer Res 2010; 70:9599-9610. PMCID: PMC3017475

Reckamp K, Gitlitz B, Chen LC, Patel R, Milne G, Syto M, Jezior D, Sara Zaknoen S. Biomarker Based Phase I Dose-Escalation, Pharmacokinetic and Pharmacodynamic Study of Oral Apricoxib in Combination with Erlotinib in Advanced Non-Small Cell Lung Cancer. Cancer 2011; 117:809-18.

Reckamp KL, Figlin RA, Burdick MD, Dubinett SM, Elashoff RM, Strieter RM. CXCR4 expression on circulating pan-cytokeratin positive non-small cell lung cancer (NSCLC) cells is associated with survival in patients with advanced NSCLC. BMC Cancer 2009; 9:213. 

Reckamp KL, Gardner BK, Figlin RA, Elashoff D, Krysan K, Dohadwala M, Mao J, Sharma S, Inge L, Rajasekaran A, Dubinett SM. Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase (MMP)-9 and a decline in serum soluble E-cadherin (sEC). J Thorac Oncol 2008; 3:117-124. 

Reckamp KL, Krysan K, Morrow JD, Newman RA, Tucker C, Elashoff RM, Dubinett SM, Figlin RA. A Phase I Trial to Determine the Optimal Biologic Dose of Celecoxib When Combined with Erlotinib in Advanced Non-Small Cell Lung Cancer. Clin Cancer Res 2006; 12:3381-8. 


This is a partial list. Full publications list available upon request. Information on this page may be self-reported and is subject to change at any time. Last updated: 03/13